Please login to the form below

Not currently logged in
Email:
Password:

Brooksby hopeful for pharma's future

The outgoing president of the Association of the British Pharmaceutical Industry, Nigel Brooksby, has warned that it is critical that the government restores faith in its relationship with pharma
The outgoing president of the Association of the British Pharmaceutical Industry (ABPI), Nigel Brooksby, has warned that it is critical that the government restores faith in its relationship with pharma.

Leaving office on May 1, Brooksby remained optimistic that government can build on a strong relationship with the industry to protect its reputation as a leader of global medicines R&D. According to the ABPI, the UK pharmaceutical sector discovers one-in-five of the world's drugs, as many as the rest of Europe combined. In 2007, the sector's exports resulted in a trade surplus for the UK economy of £4.3bn.

"We are committed to working with the government to retain leadership in the UK, provide value for money, encourage and reward innovation, assist in the uptake of new medicines and, importantly, help restore industry confidence through predictability, stability and sustainability," said Brooksby.

Brooksby, head of UK operations for sanofi-aventis, did express concern over the government's decision this year to renegotiate the Pharmaceutical Pricing Regulation Scheme (PPRS). He said it had 'dented' industry business confidence and left the integrity of the UK market environment in doubt.

Richard Ley, press spokesman for the ABPI, said: "We are, as the ABPI, concerned that the country is not as attractive as it was to global companies looking to invest money in R&D and manufacturing of pharmaceuticals."

Statistics in the ABPI annual report showed that sales of medicines accounted for 9.2 per cent of NHS costs in 2007, with an average of 46p being spent per person per day on drugs. The ABPI claims that despite these figures, patient access to innovative medicines is the lowest in Europe.

1st May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics